2024.05.10ENB Therapeutics, one of Remiges Ventures’ portfolio companies, announced clinical collaboration between Coherus and the Cancer Research Institutes using ENB-003 for the treatment of ovarian cancer

2024.04.30InFlectis BioScience, a portfolio company of Remiges Ventures in France, was awarded a grant from the National Multiple Sclerosis Society to advance IFB-048 preclinical development in multiple sclerosis. The research will be performed by Prof. Brian Popko of Northwestern University

2024.03.04Glycomine, one of Remiges Ventures’ portfolio companies, announced encouraging efficacy data from ongoing Phase2 clinical study in PMM2-CDG

2024.01.31InFlectis BioScience, a portfolio company of Remiges Ventures in France, completed enrollment of patients for the Phase 2 trial of IFB-088 for the treatment of bulbar onset Amyotrophic Lateral Sclerosis, with initial results anticipated later this year

2024.01.16Cyrano Therapeutics, a portfolio company of Remiges Ventures, secures $9.0 million Series B financing to advance clinical development of CYR-064 for treatment of Post-Viral Smell Loss

　　News　＞　

What Remiges Does >

Team >

Portfolio Companies >

Contact >

LP Portal >